Could a traditional chinese medicine help stop lung scarring?

NCT ID NCT07319598

Recruiting now Disease control Sponsor: Peking University Third Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether tetrandrine tablets can improve lung function in people with interstitial lung disease caused by connective tissue disease (like lupus or scleroderma). One hundred adults will receive either tetrandrine or a placebo for 24 weeks, alongside their usual treatments. The main goal is to see if the drug helps preserve breathing capacity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tetrandrine tablets
What this could lead to: If it works, this could provide a new treatment option to slow lung damage and improve breathing in people with connective tissue disease-related lung scarring.
What could go wrong: This is a small, early-phase (Phase 4) study with only 100 participants. The drug may not improve lung function more than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONNECTIVE TISSUE DISEASE-ASSOCIATED INTERSTITIAL LUNG DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

connective tissue disorder interstitial lung disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CONNECTIVE TISSUE DISEASE-ASSOCIATED INTERSTITIAL LUNG DISEASE INTERSTITIAL LUNG DISEASE (ILD)

Could a traditional chinese medicine help stop lung scarring?

Summary

What this could mean

Get notified about this study

Conditions

As listed by the trial registrant

Contacts and locations

Locations

More trials for these conditions